Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank

INTRODUCTION: Intravenous augmentation therapy with purified intravenous alpha-1 antitrypsin replaces the deficient protein and is the only currently approved treatment for alpha-1 antitrypsin deficiency (AATD) related lung disease. While augmentation therapy has been available for more than 20 year...

Descripción completa

Detalles Bibliográficos
Autores principales: Tonelli, Adriano R, Rouhani, Farshid, Li, Ning, Schreck, Pam, Brantly, Mark L
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802045/
https://www.ncbi.nlm.nih.gov/pubmed/20054436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802045/
https://www.ncbi.nlm.nih.gov/pubmed/20054436

Ejemplares similares